Core Viewpoint - The company, Tasly Pharmaceutical Group Co., Ltd., is set to hold a Q3 2025 earnings presentation on December 4, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Meeting Details - The earnings presentation will take place on December 4, 2025, from 15:00 to 16:00 [2][6]. - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible online [2][6]. - The meeting will be conducted in an interactive online format, allowing for real-time engagement with investors [3][5]. Group 2: Investor Participation - Investors can submit questions for the presentation from November 27, 2025, to December 3, 2025, by visiting the Roadshow Center's website or via the company's email [2][7]. - The company will address commonly asked questions during the earnings presentation [3][7]. Group 3: Company Representatives - Key representatives from the company include Mr. Cai Jinyong (General Manager), Mr. Yu Jie (Board Secretary), and Ms. Wei Jie (Chief Financial Officer) [4].

证券代码：600535 证券简称：天士力 编号：临 2025-071 号 天士力医药集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 12 月 4 日（星期四）15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.ssei nfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 27 日（星期四）至 2025 年 12 月 3 日（星期三） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 stock@tasly.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 天士力医药集团股份有限公司（以下简称"公司"）已于 2025 年 10 月 25 日发 布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第 三季度经营成果、财务状况，公司计划于 2025 年 ...

Core Insights - The introduction of the innovative biopharmaceutical Puyouke by Tianshili represents a significant breakthrough in thrombolytic therapy for acute ischemic stroke, particularly for elderly patients who face high bleeding risks during treatment [1][2] - Recent studies published in top medical journals indicate that patients treated with Puyouke experience lower rates of hemorrhagic complications compared to control groups, highlighting its unique advantages in stroke treatment [2] - The "Lung·New Life" stroke prevention project, supported by Tianshili, aims to enhance the quality and quantity of ischemic stroke treatments in line with national health strategies, focusing on training healthcare professionals and improving public awareness [3][4] Company Developments - Tianshili's Puyouke is positioned to balance effective thrombolysis with reduced bleeding risks, enhancing its market potential and expanding the company's product line in the neurology sector [2][4] - The company is actively involved in community outreach and education initiatives to improve stroke prevention and treatment awareness, particularly in underserved areas [6][5] - Tianshili's commitment to innovation and social responsibility is evident in its support for the "Lung·New Life" project, which aims to provide comprehensive stroke care and improve healthcare access [5][7] Industry Trends - The evolution of thrombolytic therapies has shifted towards safer and more effective treatments, with Puyouke exemplifying this trend through its unique molecular structure and mechanism of action [4] - The national health strategy emphasizes the need for increased access to intravenous thrombolysis treatments in medical institutions, aligning with Tianshili's initiatives [3] - The dual focus on clinical needs and technological innovation in the pharmaceutical industry is highlighted by Tianshili's approach, which serves as a model for sustainable development in China's healthcare sector [7]

Group 1 - A fruit store in Ningbo was fined 50,000 yuan for issuing 28 false invoices to Tian Shi Li Pharmaceutical Group Co., Ltd. and Tian Shi Li Di Yi Pharmaceutical Co., Ltd. [1][7] - The total amount of the false invoices was 66,800.04 yuan, which included both the price and tax [7]. - The tax authority confiscated illegal income of 6,206 yuan from the fruit store in addition to the fine [7][8]. Group 2 - Tian Shi Li Pharmaceutical Group Co., Ltd. is a publicly listed pharmaceutical company in A-shares, while Tian Shi Li Di Yi Pharmaceutical Co., Ltd. is its wholly-owned subsidiary [7]. - The case raises questions about the authenticity of transactions between the fruit store and the pharmaceutical companies, as the nature of their business dealings remains unclear [7].

Core Insights - The training program aims to enhance the capabilities of private entrepreneurs and business association leaders in the region, focusing on the implementation of the spirit of the 20th National Congress and the private enterprise symposium [1][3][5] Group 1: Political Guidance and Policy Orientation - The training emphasizes political construction as a priority, integrating the spirit of the 20th National Congress and the private enterprise symposium throughout the program [3] - It aims to help participants understand their important role as "insiders" in the private economy, aligning with national policies [3] Group 2: Comprehensive Course System - The training features a three-dimensional teaching system comprising theoretical explanations, case analyses, and on-site observations [5] - Courses include topics such as the spirit of the 20th National Congress, macroeconomic analysis, enterprise management innovation, and AI technology [5] - Participants visit leading companies in advanced manufacturing, biomedicine, and digital information sectors to learn about modern management and technological innovation [5] Group 3: Platform Functionality and Empowerment - The program adopts an innovative "training + trade" model, facilitating economic exchange meetings alongside the training [7] - Entrepreneurs and association leaders discuss upgrading regional industries and enhancing economic cooperation [7] - Initial cooperation intentions are established between various enterprises and chambers, laying the groundwork for future collaboration [7] Group 4: Training Outcomes and Future Directions - The training receives positive feedback for its precise course design and practical engagement mechanisms [7] - Participants express commitment to applying their learning to drive innovation and development in their enterprises [7] - The organization plans to continue collaborating with universities and businesses to ensure the training's effectiveness and support high-quality development in the private economy [8]

Core Insights - Shenzhen has emerged as a key engine city in the Guangdong-Hong Kong-Macao Greater Bay Area, showcasing significant achievements in capital market development during the 14th Five-Year Plan period, with over 400 billion yuan in equity financing and a leading proportion of technology companies listed [1][2] Group 1: Capital Market Development - During the 14th Five-Year Plan, Shenzhen's capital market facilitated over 400 billion yuan in equity financing, supporting advanced manufacturing projects [2] - The proportion of companies listed on the Growth Enterprise Market and the Sci-Tech Innovation Board reached 50.24%, the highest among major cities in China [2] - Shenzhen's overall R&D investment intensity reached a global leading level, with listed companies' R&D expenditure totaling 210.33 billion yuan in 2024, a 91.35% increase from 2020 [2] Group 2: Market Performance - In the first three quarters of 2025, Shenzhen's listed companies achieved a total revenue of 5.2 trillion yuan and a net profit of 457.797 billion yuan, reflecting year-on-year growth of 7.36% and 3.98%, respectively [3] - Shenzhen's securities firms ranked first nationally in performance, with public and private fund management scales among the top three [3] Group 3: Investor Engagement and Protection - During the 14th Five-Year Plan, 1,486 listed companies in Shenzhen implemented cash dividends totaling nearly 990 billion yuan, significantly exceeding the equity financing amount [4] - The regulatory authorities maintained a "zero tolerance" approach to violations, enhancing investor confidence and market integrity [4][6] Group 4: Future Directions - The Shenzhen government aims to establish a globally influential industrial financial center, focusing on high-quality development in banking, securities, insurance, venture capital, and mergers and acquisitions [7][8] - The capital market will emphasize the development of new productive forces, guiding funds towards high-tech and high-quality sectors to support industrial transformation and innovation [8]

Core Insights - Shenzhen is positioned as a core engine city in the Guangdong-Hong Kong-Macao Greater Bay Area, serving as an innovative hub for new business models and a key trade center, with a capital market that ranks among the top in China [1][2] - During the 14th Five-Year Plan period, Shenzhen's capital market achieved over 400 billion yuan in equity financing, with a leading proportion of technology companies listed, and a significant increase in overall R&D intensity [2][3] - Looking ahead to the 15th Five-Year Plan, Shenzhen aims to establish itself as a globally influential industrial financial center, focusing on high-quality capital market development [1][6] Group 1: Capital Market Development - Shenzhen's capital market has increasingly supported the real economy, with equity financing exceeding 400 billion yuan during the 14th Five-Year Plan, facilitating advanced manufacturing projects [2][3] - The proportion of companies listed on the Growth Enterprise Market and the Sci-Tech Innovation Board accounts for 50.24% of total listed companies in the region, the highest among major cities in China [2] - R&D expenditure of listed companies in Shenzhen is projected to reach 210.34 billion yuan in 2024, a 91.35% increase from 2020, with BYD leading at 54.16 billion yuan [2] Group 2: Market Performance and M&A Activity - In the first three quarters of 2025, Shenzhen's listed companies reported cumulative revenues of 5.2 trillion yuan and net profits of 457.797 billion yuan, with growth rates of 7.36% and 3.98%, respectively, surpassing national averages [3] - Shenzhen has seen 497 mergers and acquisitions since the introduction of the "M&A Six Guidelines," with transaction amounts exceeding 90 billion yuan, enhancing corporate competitiveness [3] - Over 60% of Shenzhen's listed companies are involved in overseas business, generating 580.14 billion yuan in revenue, marking an 18.11% year-on-year increase [3] Group 3: Investor Engagement and Protection - During the 14th Five-Year Plan, Shenzhen's listed companies implemented cash dividends totaling nearly 990 billion yuan, significantly exceeding equity financing amounts [4] - A total of 598 companies executed share buybacks amounting to nearly 46 billion yuan, with 40 companies receiving approval for stock buyback loans totaling 5.771 billion yuan [4] - The regulatory environment has been strengthened, with 131 cases handled by the Shenzhen Securities Regulatory Bureau, resulting in 88 administrative penalties totaling over 500 million yuan [5] Group 4: Future Directions and Strategic Goals - The Shenzhen government aims to accelerate the establishment of a globally influential industrial financial center, focusing on high-quality development across various financial sectors [6][7] - Key initiatives include enhancing the resilience of the capital market, promoting a high-level opening-up, and strengthening investor protection mechanisms [7] - The focus will be on developing new productive forces, guiding funds towards high-tech and high-quality projects, and improving the multi-tiered capital market structure [6][7]

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. has received approval from the National Medical Products Administration for its innovative biological drug "Recombinant Human Urokinase (Puyouke)" for the treatment of acute ischemic stroke (AIS), addressing the specificity issues of traditional thrombolytic drugs in the stroke field [4][9]. Group 1: Product Approval and Market Impact - The new indication approval for Puyouke follows its previous approval for treating acute ST-segment elevation myocardial infarction, enhancing its role in stroke treatment [4]. - Puyouke targets occlusive thrombus specifically, activating plasminogen at the site of occlusion, which reduces systemic activation of the fibrinolytic system, thus lowering the risk of bleeding and improving patient outcomes [7][9]. Group 2: Challenges in Stroke Treatment - China faces significant challenges in the prevention and treatment of acute ischemic stroke, with approximately 3.3 million new cases annually, making it the leading cause of death and disability among adults [6]. - Public awareness of stroke symptoms and emergency response is low, with 67%-75% of patients missing the thrombolysis window due to delayed treatment [6]. - The rate of intravenous thrombolysis is only about 10%, and endovascular treatment is less than 1%, indicating a substantial gap compared to developed countries [6]. Group 3: Innovation and Production Challenges - The development of Puyouke required overcoming multiple technical barriers, including the stability and yield of the active ingredient, recombinant human urokinase [8]. - Tasly has established a comprehensive quality control system and stable production capacity, addressing the high barriers to commercial production of unstable enzyme products [8]. Group 4: Public Health Initiatives - The "Stroke Prevention and Treatment Capacity Enhancement and Health Promotion" project, initiated by the Chinese Stroke Association and supported by Tasly, aims to improve public awareness and enhance grassroots medical capabilities in stroke prevention and treatment [10][11]. - The project focuses on educating the public about stroke prevention and early treatment, as well as improving the diagnostic and treatment skills of primary care physicians [11].

Investment Rating - The report maintains a rating of "Overweight" for the pharmaceutical and biotechnology sector [5]. Core Insights - The report highlights a significant increase in influenza-like illness (ILI) cases, suggesting a potential surge in demand for flu vaccines, respiratory virus testing, and cold medications [2][24]. - The report emphasizes the importance of clinical value in the pharmaceutical sector, advocating for investments in innovative drug chains and medical devices [3][27]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 3.29%, outperforming the CSI 300 index by 4.37 percentage points and the ChiNext index by 4.59 percentage points, ranking 5th among 31 sub-industries [1][16]. - The Hong Kong Hang Seng Medical Health Index increased by 6.8%, surpassing the Hang Seng Index by 5.4 percentage points [1][16]. Current Trends - The proportion of flu-like cases has been rising, with the ILI percentage reported at 5.5% in southern provinces and 6.1% in northern provinces, indicating a higher incidence compared to previous years [22][23]. - The report warns of a potential severe flu season in 2025, driven by changes in circulating strains and increased risks of immune evasion [2][23]. Investment Recommendations - The report suggests focusing on investment opportunities in flu vaccines, respiratory virus testing, cold medications, and special drugs due to the rising flu cases [2][24]. - Specific companies recommended for flu vaccines include Hualan Biological Engineering, Baike Biological, and Jindike; for respiratory virus testing, companies like Innotec, Shengxiang Biological, and Botao Biological are highlighted; and for cold medications, companies such as Zhongsheng Pharmaceutical, China Resources Sanjiu, and Kangyuan Pharmaceutical are suggested [2][24][26]. Key Company Earnings Forecast and Valuation - The report provides a detailed earnings forecast and valuation table for key companies, indicating a "Buy" rating for Tianjin Tasly Pharmaceutical, Innovent Biologics, and WuXi AppTec, among others [4][29]. - The earnings per share (EPS) and price-to-earnings (PE) ratios for these companies are projected to improve over the next few years, reflecting positive market sentiment [4]. Annual Investment Strategy - The report outlines a three-stage investment strategy focusing on clinical value, emphasizing the need for innovative drugs and high-end medical devices [3][27]. - It highlights the potential for growth in the innovative drug sector and the importance of domestic and international market dynamics [27][28].

Core Viewpoint - The Medical Health Index (980016) closed at 6572.66 points, down 0.65%, with a trading volume of 23.397 billion yuan and a turnover rate of 0.87% on November 14 [1] Group 1: Index Performance - Among the index constituents, 16 stocks rose while 33 stocks fell, with Ganli Pharmaceutical leading the gainers at a 2.0% increase and Yirui Technology leading the decliners at a 3.74% decrease [1] - The top ten constituents of the Medical Health Index include major companies such as WuXi AppTec, Hengrui Medicine, and Mindray Medical, with respective weights of 13.66%, 11.00%, and 7.57% [1] Group 2: Market Capitalization and Stock Prices - The total market capitalization of the top ten constituents ranges from 553.09 billion yuan for Kelun Pharmaceutical to 4603.55 billion yuan for Rihai Shenzhou, with stock prices varying from 12.25 yuan to 298.80 yuan [1] - The performance of the top ten stocks shows a mix of slight declines, with WuXi AppTec down 1.49% and Hengrui Medicine down 1.04% [1] Group 3: Capital Flow - The Medical Health Index constituents experienced a net outflow of 472 million yuan from major funds, while retail investors saw a net inflow of 388 million yuan [1] - Detailed capital flow data indicates that Ganli Pharmaceutical had a net inflow of 62.98 million yuan from major funds, despite a net outflow from retail investors [2]